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Abstract 
Background. Look-alike, sound-alike (LASA) drug names are a cause of medication errors with 
resulting patient harm and healthcare costs. This study assessed to which extent the use of the 
generic drug name, therapeutic class, health problem, and the U.S. Food and Drug Administration 
(FDA)-approved indications might be used to differentiate LASA drug pairs. 
Research design and methods. We collected information about LASA drug pairs reported by the 
FDA to have look-alike sound-alike similarities. To assess potential for differentiating LASA drug 
pairs, we compared the following drug characteristics: generic name, therapeutic class, health 
problem, and FDA-approved indication.  
Results. For the 33 FDA reported LASA drug pairs we identified a total of 432 FDA-approved 
indications. Using the generic name, therapeutic class, health problem and drug indication we were 
able to differentiate 8 (24.2%), 24 (72.7%), 25 (75.8%) and 26 (78.8%), respectively of the 33 
LASA drug pairs. Using the generic name, therapeutic class, and health problem we were able to 
distinguish 31 (7.2%), 212 (49.1%), and 269 (62.3%), respectively of the 432 FDA-approved 
indications for the LASA drug pairs. 
Conclusions. Including the FDA-approved indication in the drug prescription may be used to 
differentiate LASA drug pairs and thus, prevent wrong drug medication errors. 
Key words: Drug safety; Drug errors; Look-Like Drugs, Sound-Like Drugs, FDA, Medication 
indications  
Introduction 
Medication errors occur at all stages in medication use including ordering, transcribing, 
dispensing, and administration.[1-3] A look-alike, sound-alike (LASA) error is the erroneous 
prescription, dispensing or delivery of a drug because the name of the drug is similar in 
appearance to or sounds like another drug.[4,5]   
In 1973, Benjamin Teplitsky published the first list of look-alike or sound-alike drug 
(LASA) names.[6] The FDA has published lists of LASA generic and brand names[7,8] and 
newly FDA-identified LASA errors are subject to safety communications.[9,10] Since 2008, the 
Institute for Safe Medication Practices has also regularly published  a list of LASA drug name 
pairs.[11]   The United States (US) Pharmacopeia has identified 1,470 drugs involved in LASA 
errors.[12] 
Systematic quantitative estimates of LASA incidents are lacking. LASA errors are often 
identified through spontaneous reporting, retrospective chart review, and computer triggers. [13] 
Prior research assessed LASA errors in a specific therapeutic area,[14,15] patient population [16-
19] or healthcare setting.[16,20-23] 
LASA errors are reported cause of medication errors threatening patient safety.[24-27] 
Errors due to LASA drugs may cause patients’ harm and death.[16,19,28] It has been estimated 
that 1.4% of LASA drug errors result in adverse and harmful patient outcomes.[12] Additionally, 
LASA errors may also result in substantial healthcare costs.[27] 
To our knowledge, no studies have assessed the potential to reduce LASA errors by using 
the U.S. Food and Drug Administration (FDA) approved drug indication to differentiate LASA 
drug pairs. Thus, the aim of this study was to assess to which extent the use of the generic drug 
name, therapeutic class, health problem, and FDA-approved indications may help differentiating 
LASA drug pairs. 
  
Methods 
We collected information about LASA drug pairs reported by the FDA to have look-alike 
sound-alike similarities available at the FDA Office of Generic Drugs Name Project [7] the Drug 
Products Associated with Medication Errors website [8] and two FDA safety 
communications.[9,10] The Anatomical Therapeutic Chemical (ATC) classification system 
therapeutic class for LASA drugs were extracted from the WHO Collaborating Centre for Drug 
Statistics Methodology.[29] 
A complete list of indications for each drug was extracted from the latest available 
version of the FDA approved labels. The FDA label information was collected from the 
Labels@FDA and Drugs@FDA online databases.[30,31] The database Dailymed was searched 
as needed for labels not available at the FDA websites or for labels of drugs discontinued from 
the US market.[32] The indication information was extracted from the indications and usage 
section of the FDA label. This section provides a concise statement about the use of the drug for 
“the treatment, prevention, mitigation, cure, or diagnosis of a recognized disease or condition, or 
of a manifestation of a recognized disease or condition, or for the relief of symptoms associated 
with a recognized disease or condition.”[33] The indications and usage section may also include 
major limitations of use (e.g., use in particular subsets of the population, line of therapy status).  
The health problem information was extracted from the FDA-labeled indication. The 
health problem was defined as the disease, condition, manifestation or symptom described in the 
indications and usage section of the label. The general concept of the health problem as defined 
in the FDA-approved label was used for the analysis. We also examined the most detailed 
concept of the health problem contained in the FDA-approved label. For example, cyclosporine 
is indicated for “the treatment of patients with severe active, rheumatoid arthritis where the 
disease has not adequately responded to methotrexate.” In this case, we considered “arthritis” to 
be the general health problem, and “treatment of patients with severe active, rheumatoid 
arthritis” the most detailed health problem concept. 
Table 1 provides an example of a LASA drug pair (i.e., daunorubicin citrate liposomal 
and doxorubicin liposomal) and illustrates how a side-by-side comparison of the drug 
characteristics may help differentiating two LASA drugs that have similar generic names. 
Dunorubicin and doxorubicin cannot be differentiated using their therapeutic class or the general 
health problem. The detailed health problem may help in part to differentiate these two subtly 
different drugs and indications because while “AIDS-related Kaposi’s sarcoma” is a parent 
concept of “Advanced HIV-associated Kaposi's sarcoma” the FDA-approved indication differs in 
terms of the line of therapy and specifies that daunorubicin is the first line therapy for patients 
with advanced HIV-associated Kaposi's sarcoma. 
Table 1. Example of Differences in the Characteristics of a Look-Alike/Sound-Alike Drug 
Pair  
Generic name daunorubicin citrate liposomal doxorubicin liposomal 
Therapeutic subgroup Antineoplastic Agents Antineoplastic Agents 
General health problem Kaposi’s sarcoma Kaposi’s sarcoma 
Detailed health problem Advanced HIV-associated 
Kaposi's sarcoma 
AIDS-related Kaposi’s sarcoma 
Indication First line cytotoxic therapy for 
advanced HIV-associated Kaposi's 
sarcoma. Not recommended in 
patients with less than advanced 
HIV-related Kaposi's sarcoma. 
Treatment of AIDS-related 
Kaposi’s sarcoma in patients after 
failure of prior systemic 
chemotherapy or intolerance to 
such therapy. 
We collected the indications for all routes, dosage forms, and strengths approved for the 
each drug to account for possible changes in indications depending on those drug characteristics. 
To assess differences among LASA drug pairs, we compared each of the following drug 
characteristics: generic name, therapeutic class, health problem, and FDA-approved indication. 
We also assessed differences among LASA drug pairs including all of the above characteristics 
as a bundle.  
We assessed differences in the FDA-approved indications for each LASA drug pair to 
account for drugs that have multiple indications with different health problems or therapeutic 
class. We also assessed if the indications of each LASA drug pair were the same or different. 
Data were descriptively assessed following a structured and standardized approach. A 
standardized data abstraction form, using a spreadsheet template in MS Excel, and a checklist 
were developed and utilized by the authors to assess differences in LASA drug pairs. The data 
abstraction form included the generic name, general and detailed health problems, and 
indications described in the FDA-approved drug label and the therapeutic subclass from the 
World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) Classification 
System.[29] The data abstraction form also included characteristics of assessed drugs. Two 
authors abstracted information from the FDA approved-label independently. The results from the 
data abstraction were compared after completing the review of the labels. Discrepancies between 
authors were resolved by a third author retrieving the information from the drug label. 
Descriptive analyses were performed using MS Excel 2013. 
Results 
As of July 30, 2016, we collected information for 33 LASA drug pairs reported by the 
FDA. LASA drug pairs included 21 (31.8%) brand names and 45 (68.2%) generic names (Table 
2). The LASA drug names included a total of 60 different active ingredients. An active 
ingredient may be included in more than one LASA drug pair; 6 single active ingredients (i.e., 
hydralazine, hydromorphone, hydroxyzine, methyltestosterone, tolbutamide, and topiramate) 
were each included in 2 LASA pairs. The therapeutic classes with the highest number of LASA 
drugs included nervous system (16 drugs, representing 24.2% of all LASA drugs), alimentary 
tract and metabolism (14, 21.2%), antineoplastic and immunomodulating agents (10, 15.2%), 
and cardiovascular system (9, 13.6%). There were 4 drugs (i.e., medroxyprogesterone acetate, 
methylprednisolone acetate, prednisolone, and prednisone) with codes in 3 or more ATC 
anatomic classes. 
LASA drug pairs included a total of 432 FDA-approved indications with a median of 2 
indications per drug (range 1-77) (Table 3). Of the total 432 FDA-approved indications, 152 
(35.2%) were the same indication for both drugs in the pair and 280 (64.8%) were different. 
There were 20 drugs (30.3% of all LASA drugs) with only 1 approved indication.  
Two LASA drugs (acetohexamide and sulfisoxazole) were discontinued from the U.S. 
market as of July 31, 2016. In addition, there were changes in 2 brand names to differentiate 
LASA drugs -Levoxine changed to Levoxyl in 1994, and Omacor changed to Lovaza in 2007. 
Using the generic name, therapeutic class, general health problem and drug indication we 
were able to differentiate 8 (24.2%), 24 (72.7%), 25 (75.8%) and 26 (78.8%), respectively of the 
33 LASA drug pairs. 
Table 2. United States Food and Drug Administration-Reported Look-Alike/Sound-Alike Drug Pairs that can be Differentiate 
Using Selected Drug Characteristics 
Look-Alike/Sound-Alike Drug Pairs 
Drug Characteristics Used to Differentiate 















acetazolamide acetohexamide No Yes Yes Yes Yes 4 
Amaryl* (glimepiride) Reminyl* (galantamine hydrobromide) Yes` Yes Yes Yes Yes 5 
Amicar* (aminocaproic 
acid) Omacor* (omega-3 acid ethyl esters) Yes Yes Yes Yes Yes 5 
bupropion buspirone No Yes Yes Yes Yes 4 
chlorpromazine chlorpropamide No Yes Yes Yes Yes 4 
clomiphene clomipramine No Yes Yes Yes Yes 4 
cycloserine cyclosporine No Yes Yes Yes Yes 4 
daunorubicin doxorubicin No No No No No 0 
dimenhydrinate diphenhydramine No Yes Yes Yes Yes 4 
dobutamine dopamine No No Yes Yes Yes 3 
Durezol* (difluprednate) Durasal* (salicylic acid) Yes Yes Yes Yes Yes 5 
Flomax* (tamsulosin 
hydrochloride) Volmax* (albuterol sulfate) Yes Yes Yes Yes Yes 5 
glipizide glyburide No No No No No 0 
hydralazine hydromorphone No Yes Yes Yes Yes 4 
hydralazine hydroxyzine No Yes Yes Yes Yes 4 
hydromorphone hydroxyzine No Yes Yes Yes Yes 4 
Kaletra* (lopinavir; 
ritonavir) Keppra* (levetiracetam) Yes Yes Yes Yes Yes 5 
Lanoxin* (digoxin) Levoxine* (levothyroxine sodium) Yes Yes Yes Yes Yes 5 
*Brand name 
Look-Alike/Sound-Alike Drug Pairs 
Drug Characteristics Used to Differentiate 















Maalox Total Relief* (aluminum 
hydroxide; magnesium hydroxide; 
simethicone) 
Maalox liquid products* (bismuth 
subsalicylate) Yes No Yes Yes Yes 4 
medroxyprogesterone methyltestosterone No No Yes Yes Yes 3 
methadone Metadate* (methylphenidate hydrochloride) No Yes Yes Yes Yes 4 
methylprednisolone acetate methyltestosterone No Yes Yes Yes Yes 4 
mitoxantrone methotrexate No No No Yes Yes 2 
nicardipine hydrochloride nifedipine No Yes Yes Yes Yes 4 
prednisolone prednisone No No No No No 0 
risperidone ropinirole No Yes Yes Yes Yes 4 
sulfadiazine sulfisoxazole No No No No No 0 
Taxol* (paclitaxel) Taxotere* (docetaxel) No No No No No 0 
tolazamide tolbutamide No No No No No 0 
tolbutamide topiramate No Yes Yes Yes Yes 4 
Topamax* (topiramate) Toprol-Xl* (metoprolol succinate) Yes Yes Yes Yes Yes 5 
vinblastine vincristine No No No No No 0 
Zantac* (ranitidine hydrochloride) Zyrtec* (cetirizine hydrochloride) No Yes Yes Yes Yes 4 
 *Brand name. Note: “Yes” identifies a dug characteristic that differentiates the LASA drug pair. “No” identifies a drug characteristic that does not 
differentiate the LASA drug pair. 
  
Table 3. Indications of the Food and Drug Administration-Reported Look-Alike/Sound-Alike Drug Pairs that are Possible to 
Differentiate Using Selected Drug Characteristics 
     
Look-Alike/Sound-Alike Drug Pairs 
# of FDA 
Approved 
Indications 
Drug Characteristics Used to Differentiate 











acetazolamide 4 0 4 4 4 4 
acetohexamide 1 0 1 1 1 1 
Amicar* (aminocaproic acid) 1 1 1 1 1 1 
Omacor* (omega-3 acid ethyl esters) 1 1 1 1 1 1 
bupropion 3 0 3 3 3 3 
buspirone 2 0 2 2 2 2 
chlorpromazine 10 0 10 10 10 10 
chlorpropamide 1 0 1 1 1 1 
clomiphene 1 0 1 1 1 1 
clomipramine 1 0 1 1 1 1 
cycloserine 3 0 3 3 3 3 
cyclosporine 6 0 6 6 6 6 
daunorubicin 3 0 0 0 0 1 
doxorubicin 18 0 0 15 15 16 
dimenhydrinate 2 0 2 2 2 2 
diphenhydramine 2 0 2 2 2 2 
dobutamine 1 0 0 1 1 1 
dopamine 3 0 0 3 3 3 
Durezol* (difluprednate) 2 2 2 2 2 2 
Durasal* (salicylic acid) 1 1 1 1 1 1 
Flomax* (tamsulosin hydrochloride) 1 1 1 1 1 1 
 
 
# of FDA 
Approved 
Indications 
Drug Characteristics Used to Differentiate 











Volmax* (albuterol sulfate) 1 1 1 1 1 1 
glipizide 1 0 0 0 0 0 
glyburide 1 0 0 0 0 0 
hydralazine 2 0 2 2 2 2 
hydromorphone 2 0 2 2 2 2 
hydralazine 2 0 2 2 2 2 
hydroxyzine 14 0 14 14 14 14 
hydromorphone 1 0 1 1 1 1 
hydroxyzine 14 0 14 14 14 14 
Kaletra* (lopinavir; ritonavir) 1 1 1 1 1 1 
Keppra* (levetiracetam) 3 3 3 3 3 3 
Lanoxin* (digoxin) 2 2 2 2 2 2 
Levoxine* (levothyroxine sodium) 3 3 3 3 3 3 
Maalox Total Relief* (aluminum hydroxide; 
magnesium hydroxide; simethicone) 2 2 0 2 2 2 
Maalox liquid products* (bismuth subsalicylate) 2 2 0 2 2 2 
medroxyprogesterone 6 0 0 6 6 6 
methyltestosterone 2 0 0 2 2 2 
methadone 2 0 2 2 2 2 
Metadate* (methylphenidate hydrochloride) 2 0 2 2 2 2 
methylprednisolone acetate 59 0 59 59 59 59 
methyltestosterone 2 0 2 2 2 2 
mitoxantrone 3 0 0 2 3 3 
methotrexate 12 0 0 10 12 12 
nicardipine hydrochloride 1 0 1 1 1 1 
Look-Alike/Sound-Alike Drug Pairs 
# of FDA 
Approved 
Indications 
Drug Characteristics Used to Differentiate 











nifedipine 2 0 2 2 2 2 
prednisolone 59 0 0 1 1 1 
prednisone 77 0 0 15 18 18 
Amaryl* (glimepiride) 1 1 1 1 1 1 
Reminyl* (galantamine hydrobromide) 1 1 1 1 1 1 
risperidone 3 0 3 3 3 3 
ropinirole 3 0 3 3 3 3 
sulfadiazine 12 0 0 1 1 1 
sulfisoxazole 10 0 0 0 0 0 
Taxol* (paclitaxel) 5 0 0 2 4 4 
Taxotere* (docetaxel) 6 0 0 4 5 5 
tolazamide 1 0 0 0 0 0 
tolbutamide 1 0 0 0 0 0 
tolbutamide 1 0 1 1 1 1 
topiramate 5 0 5 5 5 5 
Topamax* (topiramate) 5 5 5 5 5 5 
Toprol-Xl* (metoprolol succinate) 4 4 4 4 4 4 
vinblastine 11 0 0 9 9 9 
vincristine 7 0 0 5 5 5 
Zantac* (ranitidine hydrochloride) 8 0 8 8 8 8 




In addition, using the most detailed health problem alone, defined in the FDA-approved 
drug label, we were able to differentiate the same number of LASA drug pairs as using the drug 
indication (26; 78.8%). Using all of the assessed drug characteristics (i.e., generic name, 
therapeutic class, general and detailed health problem, and indication) as a bundle we managed 
to differentiate the same number of LASA drug pairs and FDA-approved indications as using the 
FDA-approved indication alone. 
Likewise, using the generic name, therapeutic class and general health problem we 
differentiated 31 (7.2%), 212 (49.1%), and 269 (62.3%), respectively of the 432 FDA-approved 
indications for the 33 LASA drug pairs assessed in this study. Using only the most detailed 
health problem we differentiated the same number of LASA drug pair indications that were 
identified using the FDA-approved indication with the exception of 2 indications in the LASA 
pair daunorubicin/ doxorubicin that differ in FDA-recommended line of therapy.  
The FDA may approve the same indication for several drugs. There were 7 (21.2%) 
LASA drug pairs (daunorubicin/doxorubicin, glipizide/ glyburide, prednisolone/prednisone, 
sulfadiazine/sulfisoxazole, Taxol/Taxotere, tolazamide/ tolbutamide, and vinblastine/ vincristine) 
that had a total of 152 (35.2%) FDA-approved indications that we could not differentiate using 
the drug characteristics assessed in this study (i.e. generic name, therapeutic class, general and 
detailed health problem, and indication). 
Discussion  
The indication, or purpose of a drug, is an essential component of the information needed 
for appropriate drug selection, prescribing, and utilization. The drug indication is the link 
between the patient’s health problem and a specific drug being prescribed to a patient. This study 
provides evidence that including the FDA-approved drug indication in the prescription may be 
used to differentiate two-thirds of the LASA drugs pairs and thus, it has the potential to identify 
and prevent LASA errors and harm.  
LASA drug errors are a cause of medication errors in the US and may result in significant 
patients’ harm and health care costs. Evaluating the true incidence of LASA errors and its related 
outcomes remains a challenge due to  poor reporting, differences in definitions of medication 
errors, fear of litigation, inability to determine causality, and cost. 
Several strategies have been proposed to reduce LASA medication errors including the 
use of Tall Man lettering,[22,34] computerized provider order medication entry with (or without) 
electronic prescription transmission, medication reconciliation processes, barcode systems, and 
package changes.[1,35,36] Additional proposed measures include enhancing labeling for 
injectable medications that have similar appearing packaging, including security symbols, 
putting special labels on packaging of high-risk drugs, and revising processes for selecting, 
maintaining and updating the list of LASA drugs.[26]  
The FDA has published guidance intended to assist the industry in the selection of drug 
names for new medications as well as in the submission of safety aspects related with a proposed 
proprietary name to reduce medication errors.[37] Better pre-approval testing of drug names to 
reduce the number of confusing LASA drug pairs has also been proposed.[38] Proactive 
assessment of potential medication errors includes evaluation of potential look-alike packaging 
problems in addition to the drug names.[25] Harmonization of standards in international 
regulatory legislation has been also suggested.[39] The Joint Commission National Patient 
Safety Goals (NPSG) for 2005 required accredited organizations to identify and, at a minimum, 
annually review the list of LASA drugs and to proactively implement safety strategies to help 
prevent LASA drug related errors.[40] In 2010, the LASA NPSG was included as one of the 
Joint Commission Medication Management standards. [41] 
 In clinical practice, including the FDA-approved indication in the prescription might 
serve as a distinguishing feature to highlight and alert members of the health care team of a 
discrepancy between what would otherwise appear to be similar LASA drug pairs and thus, 
potentially prevent LASA drug errors. Other information, beyond the indication, adds little to the 
ability to differentiate drug LASA pairs. In cases where the LASA pair involves a brand name, 
the generic name may be used to differentiate the drugs. It is for this reason that many have 
urged use of the generic drug names rather than brand names for enhanced safety to avoid LASA 
errors[42] -there are fewer generic names than brand names and generic names usually refer to 
the chemical class. In addition, generic prescribing reduces the amount of information included 
in the prescription label improving clarity of the prescription.  
The patient’s health problems currently can be found in the electronic health record 
(EHR), [43] although pharmacists often do not have direct access to the patient’s EHR. Linking 
each drug to a specific health problem for which the drug is being prescribed may be used to 
differentiate LASA drug pairs. Including the health problem in the prescription would represent a 
step towards providing better information for clinicians, patients and caregivers. The FDA-
approved indication provides even further refinement with its more detailed information that 
could potentially differentiate more subtly different LASA drug pairs. The FDA-approved 
indication for example states if the drug is for treatment, prevention or palliation. The FDA-
approved indication may also contain information regarding limitations of use related to patients’ 
demographic characteristics, disease stage, and line of therapy that is often not included in the 
patient’s problem list [44] that could serve as a more specific flag for a potential misuse or 
LASA errors. 
There were several LASA drug pairs that have the same FDA-approved indication and 
thus, could not be differentiated in clinical practice using the drug characteristics assessed in this 
study. Other drug characteristics such as warnings and precautions, contraindications, population 
subgroups, route of administration, dosage form, strength, and dose recommendation and 
frequency might also be useful to differentiate LASA drug pairs that have the same indication. In 
some cases, the drugs may be therapeutically interchangeable, suggesting an erroneous 
substitution would not have serious consequences as opposed to other LASA pairs with 
completely different indications.   
There is growing consensus that including the indication in the prescription is desirable 
and feasible given emerging capabilities of electronic prescribing.[45] We have shown here one 
safety benefit that is both potentially powerful but also imperfect, since it could help differentiate 
most, but not all LASA.  Some EHR and electronic prescribing systems are already capable of 
linking the drug with the health problem list, the indication and other drug characteristics but 
engineering the workflow to make this easier and accurate remains a current work in 
progress.[46] The use of the detailed health problem and the FDA-approved indication may be 
too complex to differentiate LASA drug pairs without the use of electronic decision support 
systems. Health systems without fully integrated electronic decision support systems could still 
benefit from the use of the generic name, the therapeutic class and the general health problem to 
differentiate drug LASA pairs. For these clearly differentiated pairs inclusion of the indication 
would help pharmacists, other clinicians and patients more easily recognize and intercept LASA 
prescribing, dispensing and administration errors.  
The increasing use of electronic prescribing may reduce LASA drug errors, but might 
also potentially contribute to LASA drug errors due to picklist errors (juxtaposition picking 
errors from drug dropdown lists). The use of the indication may also potentially reduce this type 
of LASA errors. 
This study examined LASA drug pairs identified by the FDA and did not include 
indications not approved by the FDA (i.e. off-label indications). We elected to confine the scope 
of our study to approved labeled indications because we felt this would be a conservative 
approach for obtaining a valid set of established indications to cross reference with prescription 
indications.  There is no inherent reason such a system could not be used for both labeled and 
off-labeled indications.[45] An important question for the present study is how this might impact 
on our conclusion that FDA approved indications could help flag LASA medication errors. We 
believe there is no fundamental reason given drugs general pharmacologic properties (e.g. 
antibiotics are generally not used off- label for hypertension) although we cannot exclude the 
possibility that in rare cases a broadened medication list could permit a lowered bar that could as 
a result, overlook a LASA drug pair.  We could also envision a related positive byproduct that 
would potentially flag off-label uses, although we would want to be cautious about added 
alert/fatigue burden on prescribers.   
Concerns regarding the additional prescriber’s time and effort needed to specify the 
indication in the prescription and patient’s privacy have not been assessed in this study. However 
there is growing capability to automate such linkages and thereby facilitate incorporating the 
indication into the drug prescription and prescribing workflow. The Health Insurance Portability 
and Accountability Act of 1996 and other current patient confidentiality and privacy regulations 
do not preclude against the inclusion of the indication in the prescription. However, a patient can 
request not to include the indication in the prescription. More research is needed to empirically 
determine to which extent including the indication and other drug characteristics in the 
prescription prevent LASA drug errors in clinical practice.  
Conclusions 
Using the drug indication we were able to differentiate over three-fourths of assessed 
FDA identified LASA drug pairs. Including the FDA-approved indication in the drug 
prescription helps to differentiate LASA drug pairs and thus, may improve medication safety. 
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